Radiation-Induced Vaccination to Breast Cancer
Abstract
This study combines the TGFbeta neutralizing antibody, Fresolimumab, with Radiation Therapy (RT) to treat advanced metastatic breast cancer. Since this drug has been discontunued, with DOD approval, in the near future we will be switching to the small molecule TGF-beta inhibitor, Galunisertib. This report deals with Fresolimumab,which was given 5 times as either 1 mg/kg or 10 mg/kg 3-weekly schedules. RT islimited to IGRT (3 x 7.5 Gy) to 1-2 lesions with other lesions being designated assentinels to determine abscopal responses that are hypothesized to be due to RT induced vaccination. RT was started 10 days after the first and 3rd dose of Fresolimumab. The primary objectives are to assess safety, feasibility, and abscopal tumorregression and to monitor immune responses in these patients. The abscopal responses are assessed by imaging. The UCLA component is 3 fold: 1) to enroll patients into the clinical trial, 2) to assess immune responses using blood samples before, during and after treatment by multi-channel flow cytometry for immunemonitoring, 3) to examine the effects of targeting TGF-beta on the activities and numbers of breast cancer stem cells with and without irradiation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2015
- Accession Number
- AD1006289
Entities
People
- William H. Mcbride
Organizations
- University of California, Los Angeles